Daiichi Sankyo show positive results for atrial fibrillation treatment Lixiana
March 18, 2019Manufacturing and Production, Research and Development Daiichi Sankyo, Lixiana, pharma, vitamin K antagonist
Japanese firm Daiichi Sankyo has announced positive results of the first randomised controlled trial of uninterrupted Lixiana (edoxoban) in atrial …
Patient Experience: Living with two rare diseases
March 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wyburn-Mason Syndrome, acromegaly, feature, patient experience, pharma, rare disease
Dan Jeffries was diagnosed with the ultra-rare condition Wyburn-Mason syndrome at a young age, leaving him blind in one eye. …
Allergy Therapeutics’ adjuvanted birch allergoid drug shocks with Phase 3 failure
March 18, 2019Research and Development, Sales and Marketing allergy, allergy therapeutics, pharma, trial failure
UK-based biotech firm Allergy Therapeutics has been left disappointed after it became evident that its adjuvanted birch allergoid product failed …
NHS struggles to meet targets as more demand for services grows
March 18, 2019Sales and Marketing A&E, NHS, hospitals
The NHS is struggling to meet targets as the health service is being used by more patients than ever before, …
NICE to set out new opioid prescription guidelines for GPs
March 18, 2019Sales and Marketing GPs, NICE, addiction, addictive drugs, opioids, prescription drugs, withdrawal
NICE is set to develop new guidelines for GPs and healthcare professionals setting out rules for doctors regarding opioids and …
Sanofi and Regeneron’s Praluent approved in Europe to reduce CV risk
March 18, 2019Research and Development, Sales and Marketing Regeneron, Sanofi, cardiovascular, heart, praluent
Sanofi and Regeneron’s Praluent (alirocumab) has been awarded approval by the European Commission, it has emerged, as a therapy to …
Purdue Pharma vow not to profit from fast tracked opioid overdose antidote
March 18, 2019Sales and Marketing FDA, OxyContin, Purdue Pharma, nalmefene hydrochloride, opioids
The FDA has granted OxyContin drugmaker Purdue Pharma, fast track designation for opioid overdose antidote nalmefene hydrochloride (HCl) injection. However, …
Merck KGaA enters drug discovery partnership with AI firm Itkos
March 15, 2019Medical Communications, Research and Development AI, Merck, Merck KGaA, drug discovery, pharma
Merck KGaA and artificial intelligence (AI) firm Iktos have entered into a partnership, the pair have announced, to leverage the …
National Cancer Institute Director Ned Sharpless to become interim FDA Commissioner
March 15, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Following the surprise resignation of current FDA Commissioner Dr Scott Gottlieb a week earlier, Dr Norman ‘Ned’ Sharpless, Director of …
Sandoz CEO Richard Francis to step down
March 15, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Richard Francis is set to step down his role as Chief Executive of Novartis’ generics arm Sandoz after five years’ …
Roche scores two EU approvals in haemophilia and rare autoimmune disease
March 15, 2019Medical Communications EC, EU, Europe, Roche, haemophilia, rare diseases
The European Commission (EC) has approved Roche’s haemophilia treatment Hemlibra (emicizumab). The approval comes as the EC approved Roche’s MabThera …
MSD’s Keytruda/chemo combo nabs EU approval in first-line metastatic squamous lung cancer
March 15, 2019Medical Communications, Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
MSD’s anti-PD-L1 therapy Keytruda (pembrolizumab) has been awarded marketing authorisation in Europe for the first-line treatment of adult patients with …
Top Ten most popular articles on Pharmafile.com this week!
March 15, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Acadia Pharmaceuticals, FDA, Sandoz, brexit, genomics, pharma, pharmacovigilance, top 10
The US Department of Justice has launched an investigation into the sales and marketing practices of San Diego firm Acadia …
Pfizer CEO Ian Read’s pay packet cut from $27.9m to $19.5m
March 15, 2019Medical Communications CEO, Ian Read, Pfizer, compensation, pay packet, salary
Ian Read has seen his total compensation cut from a sum of $27.9 million in 2018 to $19.5 million this …
Roche and Chugai’s Hemlibra scoops up EU approval in the prevention of severe haemophilia A without factor VIII inhibitors
March 14, 2019Sales and Marketing Chugai, Hemlibra, Roche, haemophilia, pharma
Roche has announced along with its partner Chugai that Hemlibra (emicizumab) has secured approval from the European Commission as a …
Celgene’s Abraxane combo flops in phase 3 cancer trials
March 14, 2019Research and Development Abraxane, Celgene, clinical trials, pharma, trials
Celgene’s Abraxane, in combination gemcitabine, has failed to meet its primary endpoint in a pivotal Phase 3 trial of patients …
New class of drugs offer alternative to statins
March 14, 2019Research and Development cholesterol, health, imperial college london, research, statins
A new class of cholesterol lowering drugs may help patients who are unable to take statins, according to a study …
Sandoz CEO Richard Francis to step down
March 14, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Novartis, Sandoz, appointment, pharma
Richard Francis is set to step down his role as Chief Executive of Novartis’ generics arm Sandoz after five years’ …
Califonia court rules J&J must pay woman with mesothelioma $29 million
March 14, 2019Medical Communications, Sales and Marketing
A California jury has ordered American healthcare conglomerate Johnson & Johnson to pay more than $29 million to a woman …
National Cancer Institute Director Ned Sharpless to become interim FDA Commissioner
March 13, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Ned Sharpless, Scott Gottlieb, appointment, pharma
Following the surprise resignation of current FDA Commissioner Dr Scott Gottlieb a week earlier, Dr Norman ‘Ned’ Sharpless, Director of …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
